Literature DB >> 15878683

Plasmid DNA vaccination.

Kris Huygen1.   

Abstract

Plasmid DNA vaccination against tuberculosis is a very powerful and easy method for the induction of strong humoral responses, CD4+ mediated secretion of Th1 cytokines and CD8+ mediated CTL activity in mice. Tuberculosis DNA vaccines have not been assessed so far in humans, and clinical trials with DNA in general have been somewhat disappointing. However, numerous studies have reported on the potent priming capacity of plasmid DNA for Th1 and CD8+ mediated immune responses, which can be boosted subsequently by recombinant protein or recombinant pox-viruses. With respect to tuberculosis, prime/boost regimens with Mycobacterium bovis BCG vaccine are particularly promising and warrant further analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878683     DOI: 10.1016/j.micinf.2005.03.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  19 in total

1.  Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines.

Authors:  Sushila D'Souza; Marta Romano; Johanna Korf; Xiao-Ming Wang; Pierre-Yves Adnet; Kris Huygen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine.

Authors:  Xun Sun; Chester Provoda; Kyung-Dall Lee
Journal:  J Control Release       Date:  2010-07-07       Impact factor: 9.776

3.  DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice.

Authors:  Francisco M Teixeira; Henrique C Teixeira; Ana Paula Ferreira; Michele F Rodrigues; Vasco Azevedo; Gilson C Macedo; Sergio C Oliveira
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Designing and Construction of a DNA Vaccine Encoding Tb10.4 Gene of Mycobacterium tuberculosis.

Authors:  Samira Rashidian; Roghayeh Teimourpour; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2016

5.  Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.

Authors:  Marta Romano; Virginie Roupie; Xiao M Wang; Olivier Denis; Fabienne Jurion; Pierre-Yves Adnet; Rachid Laali; Kris Huygen
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

6.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

Review 7.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

Review 8.  Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.

Authors:  Samuel M Behar; Joshua S M Woodworth; Ying Wu
Journal:  Expert Rev Vaccines       Date:  2007-06       Impact factor: 5.217

9.  Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.

Authors:  Felicitat Todolí; Alhelí Rodríguez-Cortés; María Del Carmen Núñez; Márcia D Laurenti; Silvia Gómez-Sebastián; Fernando Rodríguez; Eva Pérez-Martín; José M Escribano; Jordi Alberola
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 10.  Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Authors:  Stephan Olschläger; Lukas Flatz
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.